PFM
Privium Fund Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.17M | Sell |
44,700
-15,397
| -26% | -$747K | 0.47% | 22 |
|
|
2025
Q1 | $2.05M | Buy |
60,097
+25,100
| +72% | +$854K | 0.53% | 24 |
|
|
2024
Q4 | $1.38M | Buy |
34,997
+4,650
| +15% | +$183K | 0.31% | 30 |
|
|
2024
Q3 | $1.43M | Buy |
30,347
+3,000
| +11% | +$141K | 0.35% | 31 |
|
|
2024
Q2 | $1.45M | Buy |
27,347
+14,600
| +115% | +$776K | 0.37% | 39 |
|
|
2024
Q1 | $869K | Hold |
12,747
| – | – | 0.23% | 49 |
|
|
2023
Q4 | $842K | Buy |
12,747
+5,547
| +77% | +$366K | 0.23% | 46 |
|
|
2023
Q3 | $327K | Buy |
7,200
+1,200
| +20% | +$54.5K | 0.1% | 64 |
|
|
2023
Q2 | $342K | Hold |
6,000
| – | – | 0.1% | 65 |
|
|
2023
Q1 | $271K | Buy |
+6,000
| New | +$271K | 0.09% | 65 |
|
|
2022
Q2 | – | Sell |
-3,750
| Closed | -$235K | – | 260 |
|
|
2022
Q1 | $235K | Buy |
+3,750
| New | +$235K | 0.05% | 118 |
|